U.S. equity futures moved lower Tuesday morning as a pickup in geopolitical tensions between the United States and Iran pushed crude prices higher and raised fresh questions about near-term inflation and the Federal Reserve's policy flexibility.
By 06:27 ET (10:27 GMT), S&P 500 futures were down 39 points, or about 0.5%, while Nasdaq 100 futures had fallen 379 points, or 1.3%. Dow Jones futures were largely unchanged.
Macro backdrop
Markets responded to a reassessment of how quickly tensions between Washington and Tehran might ease, with traders factoring in the possibility of higher energy costs. The prospect of rising oil prices has renewed concerns that an energy-driven inflation impulse could constrain the Federal Reserve's ability to cut interest rates.
Notable premarket movers
A number of individual equities registered outsized moves ahead of the cash session, driven by analyst actions, quarterly results and clinical trial developments.
Duolingo climbed 3.5% after DA Davidson upgraded the language-learning platform to Buy from Neutral and lifted its price target to $160. Citi also raised its target to $140 from $101. The company said it will acquire London-based animation studio Animade. DA Davidson highlighted what it sees as underappreciated improvements to Duolingo's core product, marketing approach and monetization engine.
Duos Technologies jumped 5.9% after reporting second-quarter earnings of $1.61 per share, versus analyst expectations for a loss of $0.02 per share. The quarter included a $53.2 million gain from the sale of its New APR Energy investments. Revenue increased 30% year-over-year to $6.18 million, and the company recorded its first positive operating quarter since shifting toward data-center infrastructure.
Amylyx Pharmaceuticals surged 24.9% ahead of topline results from its Phase 3 LUCIDITY trial of avexitide, an experimental treatment for post-bariatric hypoglycemia. The company said it would release the data Tuesday morning and host a conference call at 8 a.m. ET. The readout is being closely watched because avexitide is among the most advanced treatments in development for the condition.
The anticipated Amylyx data also appeared to lift speculative interest in other small biotechs working on similar indications. Vogenx rallied 31.1% as investors treated Amylyx's expected results as a potential read-through for Vogenx's own therapy for post-bariatric hypoglycemia. Vogenx only began trading on the Nasdaq Capital Market on Aug. 12 following its IPO, leaving what remains a relatively thin float particularly susceptible to speculative swings.
Profusa exploded 95.6% after its latest reverse stock split took effect. The 1-for-4 split reduced shares outstanding from roughly 2.42 million to about 606,000, creating an exceptionally thin public float that can magnify price moves on modest demand changes. The company has also signed an option agreement to acquire G3 Vision Labs and has a pending letter of intent for the PanOmics multi-omics diagnostics platform, developments that have added to speculative interest.
On the downside, Baidu fell 4.1% after reporting second-quarter results that missed analyst expectations on both the earnings and revenue lines. Baidu reported earnings of RMB7.22 per share, below the RMB9.84 consensus, while revenue came in at RMB31.33 billion versus a forecast of RMB31.95 billion and declined 4% from a year earlier.
DocGo slid 12.7% after reporting an adjusted loss of $0.16 per share, wider than the $0.10 per-share loss analysts had expected, while revenue of $73.4 million missed estimates of $75.4 million. Revenue declined 8.7% year-over-year, a change the company said largely reflected the wind-down of migrant-related contracts. Management noted that the underlying business showed strength, with revenue excluding migrant-related activity up 19% and medical transportation revenue reaching a record $52 million.
Fabrinet dropped 8.6% despite reporting a quarterly beat. The company posted revenue of $1.316 billion, topping expectations of roughly $1.27 billion, and non-GAAP earnings of $4.10 per share, above the $3.81 consensus. The market's negative reaction suggests investors were focused on concerns below the headline numbers rather than the quarter's top-line and earnings beats.
What to watch
- Oil price moves and any further escalation or de-escalation in U.S.-Iran tensions, given the potential implications for inflation and central bank policy.
- Data releases and conference calls tied to high-profile clinical readouts, notably Amylyx's LUCIDITY topline release and the company's scheduled call at 8 a.m. ET.
- Second-quarter earnings and guidance from individual companies, where misses have triggered sizable stock reactions even when headline figures beat expectations.
Markets opened the day with a clear sensitivity to geopolitical risk and a pronounced focus on company-specific news that is driving dispersion among individual stocks.